In:
Chemotherapy, S. Karger AG, Vol. 59, No. 3 ( 2013), p. 167-175
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Chemotherapy with 〈 smlcap 〉 L 〈 /smlcap 〉 -asparaginase is associated with hepatotoxicity resulting in organ dysfunction in patients with preexisting liver disorders. This study investigated the protective effect of 〈 smlcap 〉 L 〈 /smlcap 〉 -carnitine during chemotherapy in a steatotic rat liver model. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Livers from nonsteatotic and steatotic rats were tested in an isolated liver reperfusion model adding 〈 smlcap 〉 L 〈 /smlcap 〉 -asparaginase and 〈 smlcap 〉 L 〈 /smlcap 〉 -carnitine to the reperfusate. Portal venous pressure (PVP), hepatic oxygen consumption, aspartate aminotransferase, lactate dehydrogenase, glutamate dehydrogenase and α-glutathione S-transferase levels were assessed. Further histopathological analysis was performed and cytotoxicity was verified in vitro. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 〈 smlcap 〉 L 〈 /smlcap 〉 -Asparaginase induced toxicity in fatty livers whereas low toxicity was observed in normal livers. 〈 smlcap 〉 L 〈 /smlcap 〉 -Carnitine induced a decline in PVP and oxygen consumption, and reduced parenchymal and mitochondrial damage in fatty livers. Cytotoxicity of 〈 smlcap 〉 L 〈 /smlcap 〉 -asparaginase was not impaired by the presence of 〈 smlcap 〉 L 〈 /smlcap 〉 -carnitine. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Our study emphasizes the potential of 〈 smlcap 〉 L 〈 /smlcap 〉 -carnitine to reduce 〈 smlcap 〉 L 〈 /smlcap 〉 -asparaginase-induced hepatotoxicity in patients with preexisting liver disorders.
Type of Medium:
Online Resource
ISSN:
0009-3157
,
1421-9794
Language:
English
Publisher:
S. Karger AG
Publication Date:
2013
detail.hit.zdb_id:
1482111-4
SSG:
15,3
